Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
复制标题
DOI：
10.2337/dci20-0022
复制
发表时间：
2020-07-01
期刊：
影响因子：
16.2
通讯作者：
Franks, Paul W.
中科院分区：
文献类型：
--
作者：
Chung, Wendy K.;Erion, Karel;Franks, Paul W.
医学科学、人类生物学、数据科学和技术的进步融合在一起，使人们能够对被称为“糖尿病”的表型产生新的见解。“世界各地的人群对这种疾病的了解越来越多，阐明了糖尿病的表现方式，其可变的患病率以及最佳治疗方法在人群之间的差异。与此同时，重点一直放在开发工具，用于将精准医学应用于多种疾病。本共识报告介绍了美国糖尿病协会（ADA）与欧洲糖尿病研究协会（EASD）合作的糖尿病精准医学计划，包括其使命，该领域的现状和未来前景。专家们就精准诊断和精准治疗（包括预防和治疗）领域提出了意见，并强调了实施精准糖尿病医学的关键障碍和机遇，以在地球仪范围内提供更好的护理和结果。精确诊断已经可行且有效的情况（即，单基因型糖尿病），同时讨论了全球实施复杂型糖尿病精确诊断的主要障碍。精确治疗的情况也类似，由于糖尿病在个体患者体内的发展方式，适当的治疗往往会随着时间的推移而改变。这份共识报告描述了精准糖尿病医学的基础，同时强调了实现其潜力还需要做些什么。这与随后的详细循证审查（2022年到期）相结合，将为糖尿病的精准医学提供路线图，有助于改善所有糖尿病患者的生活质量。
The convergence of advances in medical science, human biology, data science, and technology has enabled the generation of new insights into the phenotype known as "diabetes." Increased knowledge of this condition has emerged from populations around the world, illuminating the differences in how diabetes presents, its variable prevalence, and how best practice in treatment varies between populations. In parallel, focus has been placed on the development of tools for the application of precision medicine to numerous conditions. This Consensus Report presents the American Diabetes Association (ADA) Precision Medicine in Diabetes Initiative in partnership with the European Association for the Study of Diabetes (EASD), including its mission, the current state of the field, and prospects for the future. Expert opinions are presented on areas of precision diagnostics and precision therapeutics (including prevention and treatment), and key barriers to and opportunities for implementation of precision diabetes medicine, with better care and outcomes around the globe, are highlighted. Cases where precision diagnosis is already feasible and effective (i.e., monogenic forms of diabetes) are presented, while the major hurdles to the global implementation of precision diagnosis of complex forms of diabetes are discussed. The situation is similar for precision therapeutics, in which the appropriate therapy will often change over time owing to the manner in which diabetes evolves within individual patients. This Consensus Report describes a foundation for precision diabetes medicine, while highlighting what remains to be done to realize its potential. This, combined with a subsequent, detailed evidence-based review (due 2022), will provide a roadmap for precision medicine in diabetes that helps improve the quality of life for all those with diabetes.